Trial · NCT07589387
Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
NCT07589387, Not applicable, Recruiting, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3. Trials, record NCT07589387. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07589387
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
- NCT number
- NCT07589387
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 2,800 participants, estimated
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Diabete Mellitus
- Interventions
Implementation of program based on WHO HEARTS-D guidelines, Metformin, Glimepiride, Point-of-care blood glucose monitor (glucometer) and compatible test strips, HEARTS-D training and quarterly supportive supervision for community health extension workers (CHEWs)
- First posted
- 2026-05-15
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose of quarterly supportive supervision visits measured by the proportion of observed/expected visits during the implementation period. | 36 months | Primary Implementation Outcome: Description: Dose of quarterly supportive supervision visits measured by the proportion of observed/expected visits during the implementation period. |
| Primary | Difference in 6-month rolling average of blood glucose control in patients with diabetes (random blood glucose ≤11.1 mmol/L while receiving treatment; or fasting plasma glucose/HbA1c within target, as available) per WHO HEARTS-D, pre- vs. implementation | 36 months | Primary effectiveness outcome: The primary outcome will be the difference in the 6-month rolling average of blood glucose control among patients with diabetes, control defined as random blood glucose ≤ 11.1 mmol/L (or fasting plasma glucose/HbA1c within target, as available) while receiving treatment, in accordance with HEARTS-D, between the pre-implementation and implementation periods. |
| Secondary | Difference in 6-month rolling average diabetes treatment (proportion of eligible patients prescribed any glucose-lowering medication) between pre-implementation and implementation periods | 36 months | Secondary Effectiveness Outcome (diabetes treatment): 6-month rolling average of diabetes treatment levels in the pre-implementation and implementation periods. |
| Secondary | Difference in 6-month rolling average blood sugar control (per WHO HEARTS-D: fasting plasma glucose <126 mg/dL, postprandial <160 mg/dL, or HbA1c <7%) between pre-implementation and implementation periods | 36 months | Secondary Effectiveness Outcome (blood sugar control): 6-month rolling average of blood sugar control in the pre-implementation and implementation periods. Control will be defined according to the WHO HEARTS-D module2, specifically: fasting glucose \<126 mg/dl, postprandial glucose \<160 mg/dl, or HbA1c \<7%. |
| Secondary | Difference in 6-month rolling average mean fasting plasma glucose (mg/dL) between pre-implementation and implementation periods | 36 months | Secondary Effectiveness Outcomes (mean fasting glucose levels): 6-month rolling average of mean fasting glucose levels in the pre-implementation and implementation periods. |
| Secondary | Proportion of selected primary health centers (PHCs) that participated in baseline diabetes training (A ÷ B; A = PHCs that participated, B = total selected PHCs) | 36 months | Secondary Implementation Outcome: A = Number of PHCs who participated in baseline diabetes training B = Total number of selected PHCs Calculation: A ÷ B |
| Secondary | Proportion of selected PHCs that received at least one supportive supervision visit in the past 12 months (A ÷ B; B = total selected PHCs) | 36 months | Secondary Implementation Outcome: A = Number of PHCs who received at least one supportive supervision visit in the past 12 months B = Total number of selected PHCs Calculation: A ÷ B |
| Secondary | Proportion of eligible PHCs that received at least one audit-and-feedback report within the past 3 months (A ÷ B) | 36 months | Secondary Implementation Outcome: A = Number of PHCs who received at least an audit and feedback report within the past 3-months B = Total number of selected PHCs Calculation: A ÷ B |
| Secondary | Percentage of PHCs with a working blood glucose monitor on-site on the day of assessment (last supervision visit) (A ÷ B) | 36 months | Secondary Implementation Outcome: A = Number of PHCs with a working blood glucose monitor at the site on the day of assessment (time point: last supervision visit) B = Total number of selected PHCs Calculation: A ÷ B |
| Secondary | Percentage of PHCs with diabetes medicines available on-site on the day of assessment (last supervision visit) (A ÷ B) | 36 months | Secondary Implementation Outcome: A = Number of PHCs with diabetes medicines available on the day of assessment (time point: last supervision visit) B = Total number of selected PHCs Calculation: A ÷ B |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01HL144708 | Hypertension Treatment in Nigeria Program | OJJI, DIKE BEVIS; HUFFMAN, MARK D | UNIVERSITY OF ABUJA | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2019 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07589387
GET https://conductscience.org/api/trials/v1/NCT07589387/registered